Skip to main content
Fig. 4 | Orphanet Journal of Rare Diseases

Fig. 4

From: Efficacy and pharmacokinetics of betaine in CBS and cblC deficiencies: a cross-over randomized controlled trial

Fig. 4

Plasma methionine (Met) after 1 month of treatment at 100 mg/kg/day (light grey) or 250 mg/kg/day (dark grey) of betaine in pyridoxine non responsive CBS (pnrCBS) (A) and cblC patients (B). Multivariate analysis show a significant effect of interaction between betaine dose × period (0.73 [0.09; 1.37], p 0.03) and type of disease (CBS vs. cblC deficiency, − 1.40 [− 2.61; − 0.19], p 0.03)

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172